Curis Inc (CRIS)
Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3.
| Company Name: |
Curis Inc |
| Website: |
www.curis.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding CRIS: |
2 |
| Total Market Value Held by ETFs: |
$3.36M |
| Total Market Capitalization: |
$90.00M |
| % of Market Cap. Held by ETFs: |
3.73% |
|
|
April 18, 2024 • 7:05 PM Eastern
Strong Buy (3.50 out of 4)
100th percentile
|
|
Free CRIS Email Alerts:
